OUR BELIEF IN THE CURE
The Homerun Cure™ for Cancer Starts Now
The Cure Starts Now represents something truly different – a grassroots effort dedicated to, not just fighting one cancer, but the elimination of all cancers. We believe as the experts do; that in order to truly cure cancer you have to focus on:
- those cancers that are immune to conventional treatments
- those cancers for which there are no treatments
- those cancers that affect children
- and those cancers that are the biggest bullies
We call this the Homerun Cure, but the idea isn’t new. As a matter of fact, this Homerun strategy dates back to the early 1900’s when bold advances in cancer research were made, leading to the invention of surgical efforts, radiation and finally chemotherapy. But the advancements stopped. Resources were prioritized for those cancers that affected the most people rather than those we could learn the most from, and the focus shifted from cures to treatments.
Never satisfied to wait for the next great research project, The Cure Starts Now and our partners actively seek to create brand new collaborations and protocols that were previously thought to be too ambitious or impossible.
In order to effectively combat DIPG, a comprehensive strategy must be implemented that accounts for patients in all stages of diagnosis while balancing the scientific merits of research. With this in mind, four main concentrations have been identified that are at the core of all research funded by The Cure Starts Now Medical Advisory Council and the DIPG Collaborative. They include:
In order to effectively target DIPG it is important to understand how it develops, thrives and what genomic and demographic traits may coincide with its diagnosis. Starting in 2011 an ambitious project was undertaken at Cincinnati Children’s Hospital, funded as part of a joint effort of The Cure Starts Now Foundation, Reflections of Grace Foundation and the Jeffrey Thomas Hayden Foundation. Ultimately this would become the DIPG Registry, the largest informational project ever initiated for DIPG and a model for other cancer registries. By 2013, the partnering institutions numbered 44 hospitals from 7 countries and funding was renewed by the entire DIPG Collaborative. Its goal would be to collect linked data from four areas: demographics, radiological, tissue and genomics. In 2018, the Registry serves as the largest database of DIPG data, serving to launch trials around the world and multiple published papers featuring previously unknown DIPG statistics and characteristics.
This is the research from ground up. Derived from the information we discover about DIPG, these are the trials that start as little more than biopsy trials, mouse modeling or even test tube experiments. As they advance through phases they will become the cures of tomorrow, custom built to fight DIPG.
This is the research that treats patients currently diagnosed with DIPG. Although historically this was mainly treatments substantially derived from other cancer protocols and applied to DIPG, today we are seeing the very first trials that started back in 2011 in the informational stage, moved through the translational phase and have now just become clinical trials that are unique to DIPG. Still, much of current clinical trials in any form of cancer may be effectively “hunches” where a researcher may see a particular chemotherapy having an effect on another type of cancer that is similar to DIPG and starts a trial. Regardless, it will always be a crucial element of any funding cycle to ensure treatment options for patients currently in the fight.
As DIPG is harbored within the blood brain barrier, an effective treatment is only as good as our ability to reach the tumor cells. Because of this we must also develop strategies to either reach the tumor physically or with innovative methods such as ultrasound.